iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
08. Dezember 2022 02:00 ET
|
iOnctura
Geneva, Switzerland, 8 December 2022 -- iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways,...
iOnctura expands Advisory Board
27. September 2022 02:00 ET
|
iOnctura
Geneva, Switzerland, 27 September 2022 -- iOnctura SA, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways,...
iOnctura Presents Data at AACR Demonstrating its Unique Mechanism of Action for Clinical Stage ATX Inhibitor IOA-289
08. April 2022 13:00 ET
|
iOnctura
GENEVA, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical-stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, has...
iOnctura to Present Preclinical Data on its Clinical Stage Autotaxin Inhibitor, IOA-289, at AACR
09. März 2022 02:00 ET
|
iOnctura
GENEVA, March 09, 2022 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical-stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, will present...
iOnctura Shows No Dose-limiting Toxicity and Reduced T-regs in Solid Tumor Study of PI3Kδ Inhibitor IOA-244 Presented at ESMO-IO
09. Dezember 2021 02:00 ET
|
iOnctura
GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is...
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies
09. Dezember 2021 02:00 ET
|
iOnctura
GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is...
iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December
23. November 2021 02:00 ET
|
iOnctura
GENEVA, Nov. 23, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it will...
iOnctura Presents Compelling Preclinical Data on its Clinical Stage Autotaxin Inhibitor IOA-289 at SITC
12. November 2021 08:00 ET
|
iOnctura
GENEVA, Switzerland, Nov. 12, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, presented...
iOnctura Clinical Expansion Positions Lead PI3Kδ Inhibitor IOA-244 for Potential Registration Studies in Metastatic Uveal Melanoma
08. November 2021 02:00 ET
|
iOnctura
Expansion of DIONE-01 supports subsequent transition to registration studies in metastatic uveal melanomaDIONE-01 trial design expanded with multiple cohorts including solid and hematologic...
iOnctura to Share Preclinical Data on IOA-289 at SITC in November
02. November 2021 03:00 ET
|
iOnctura
GENEVA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces that it will...